Addison's Disease treatment Market - Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

Addison's Disease Treatment market is projected to register a CAGR of 4.1% during the forecast period (2022 - 2027).

COVID-19 pandemic has significantly impacted Addison's disease, a rare disease treatment market. The rise in COVID-19 cases has led to global healthcare services shifting their resources toward COVID-19 care while impacting patients with rare diseases. According to the Eurordis International Survey, rare disease patients seemed to have a worse experience than chronic disease patients due to the pandemic. According to the study published by the National Center for Biotechnology Information in 2021, it has been found that the adrenal system is one of the most highly affected organ systems in the body during acute active infection in individuals with COVID-19 infection who require hospitalization. The pandemic led to the shutdown of companies and other non-healthcare businesses. The lack of healthcare services and canceled/postponed appointments result in the underdiagnosis of rare disease patients, negatively impacting the market.

The factors propelling the market's growth are rising incidences of Addison's disease globally, growing awareness regarding adrenal insufficiency, and rising healthcare expenditure in the countries.

The rising incidences of Addison's disease are the key factor driving the market's growth over the forecast period. According to an article published by the National Center for Biotechnology Information in 2021, titled "Adrenal Insufficiency in Patients," it has been found that one in 10,000 newborns are affected by congenital adrenal hyperplasia, an inherited form of primary adrenal insufficiency. In addition, the increasing number of tuberculosis cases is also causing adrenal insufficiency disease among people. According to the statistics published by the Centers for Disease Control 2021, 7,860 cases of tuberculosis were reported in the United States in 2021. In addition, about 13 million in the United States are affected by latent tuberculosis infection.

However, the high costs associated with the treatment medications, the lack of awareness among people regarding Addison's disease, and the inability to diagnose the disease early are likely to hinder the market's growth.

Key Market Trends

Oral Route is Expected to Have the Significant Market Share

The factors propelling the growth of the oral segment are easy to top consume and are better replacement therapy for the disease.

The most common oral drugs used for the treatment include corticosteroids such as hydrocortisone, prednisone, or methylprednisone, and fludrocortisone acetate, which replaces the cortisol and aldosterone in the body, which the body lacks to produce. According to the study published by the National Center for Biotechnology Information in 2020, it has been observed that oral hydrocortisone and fludrocortisone are found to have the potential to simulate the physiological serum cortisol level in the body.

In addition, the increasing number of tuberculosis cases is also causing adrenal tuberculosis, leading to adrenal insufficiencies in patients, likely increasing the demand for disease treatment. Adrenal insufficiency also occurs due to direct glandular involvement, extra-adrenal infection, and anti-tuberculosis medication.

Moreover, the company focusing on developing oral medications for treating patients with Addison's disease is also likely to increase the market growth over the forecast period. For instance, in February 2022, Diurnal announced that the first patient was dosed in its phase II European clinical trial of modified-release hydrocortisone for treating people with adrenal insufficiency (AI), also known as Addison’s disease.

North America is Expected to Have the Significant Market Share

North America is anticipated to have a significant share, owing to the factors such as increasing disease instances in the region, growing demand for new generation technologically integrated advanced therapeutic drugs for swift and long-term therapy, and a well-established healthcare infrastructure.

The increasing number of tuberculosis or adrenal tuberculosis cases causes adrenal insufficiency in patients by destructing the adrenal cortex and hypertrophy of the adrenal glands with caseating granulomas, thus, increasing the demand for better treatment in the region. Adrenal insufficiency also occurs due to direct glandular involvement, extra-adrenal infection, or anti-tuberculosis medication. According to the statistics published by the Centers for Disease Control, in 2021, it has been found that 35.8% of Non-Hispanic Asian persons, 29.7% of Hispanic people, and 11% of Non-Hispanic White people have tuberculosis disease in the United States.

Moreover, the increasing research and development activities and increasing focus of the companies in developing treatments for Addison's disease is further boosting the market's growth in the region. For instance, in January 2022, Antares Pharma announced positive results from a Phase I study for ATRS-1902 for adrenal crisis. ATRS-1902 is being developed to treat acute adrenal insufficiency, an adrenal crisis, in adults and adolescents.

Competitive Landscape

Addison's disease treatment market is moderately competitive with many players. The players focus on developing drugs to treat the disease and withhold their position in the market. Some key players are Bristol-Myers Squibb Company, Merck KGaA, Sandoz International GmbH, Pfizer Inc., and Takeda Pharmaceutical Company Limited.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.